Jinling Pharmaceutical Company (000919) Fair Value & Analysis

Healthcare · CN · Market cap 3.9B CNY

Below-average quality, and screening another 47% overvalued on our models.

What matters now

• The price sits above even our optimistic bull case (¥4.28). The favourable scenario is already priced in.
• Weak quality (42/100) and above fair value at the same time, the margin of safety is missing on both counts.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 21, 2026.

How to read this chart

60‑month range ¥5.13 – ¥11.36 · fair‑value band ¥2.57 – ¥4.28 · the ¥6.45 price screens above the ¥3.44 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 21, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Jinling Pharmaceutical Company (000919) currently trades at ¥6.45, while our model-based Fair Value estimate is ¥3.44, implying the stock looks roughly 46.7% overvalued today. The Quality Score stands at 42/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).

Over the trailing twelve months, Jinling Pharmaceutical Company generated revenue of 3.2B CNY at a net margin of 1.9%. Revenue declined 5.1% year over year. It earns a return on equity of 1.2%. The balance sheet holds a net cash position of 1.6B CNY. Fundamentals as of Jul 21, 2026

Our scenario range runs from ¥2.57 (bear case) to ¥4.28 (bull case); at ¥6.45, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 34% below its 52-week high and 8% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at -47%, 000919 screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Widest divergence: Asset-Based (¥4.07) versus Earnings-Based (¥0.5200). Highest evidence: Growth DCF (80).

Key figures & financial health

Quality Score breakdown

About the company

Jinling Pharmaceutical Company Limited, together with its subsidiaries, manufactures and sells pharmaceuticals and medical devices in China and internationally.

Full company description

Jinling Pharmaceutical Company Limited, together with its subsidiaries, manufactures and sells pharmaceuticals and medical devices in China and internationally. It offers Mailuoning injection and oral solution for the treatment of thromboangiitis and arteriosclerosis obliterans, as well as cerebral and venous thrombosis; Sulifei, a ferrous succinate tablet for the prevention and treatment of iron deficiency anemia; Lentinan injection, an adjuvant therapy for the treatment of malignant tumors; and absorbable gelatin sponges for the treatment of wound bleeding and trauma hemostasis. The company also provides traditional Chinese medicines, chemical medicines, active pharmaceutical ingredients, and pharmaceutical intermediates. In addition, it engages in elderly care services, rehabilitation therapy, psychological counseling, and end-of-life care; hospital management; technical services; and healthcare investment activities. The company was incorporated in 1998 and is headquartered in Nanjing, China.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Jinling Pharmaceutical Company reported revenue of ¥3.2B in FY2025 versus ¥2.8B in FY2021, a compound +3.3%/yr. Reported net income was ¥53.9M in FY2025, compounding −18.2%/yr from FY2021.

000919 screens 47% overvalued. Compare with Jiangsu Hengrui Pharmaceuticals Co →

Peer Group

Drug Manufacturers - Specialty & Generic · 626 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 0: the price sits above our fair-value range.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 21, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.